Influence of fibrate treatment on malondialdehyde-modified LDL concentration.
BACKGROUND
Drug therapy is considered essential to the clinical prevention of atherosclerotic lesions in patients with diabetes mellitus (DM).


METHODS
To confirm the effects of fibrate therapy, we determined low-density lipoprotein (LDL) size by gradient gel electrophoresis and malondialdehyde-modified LDL (MDA-LDL) concentrations by enzyme-linked immunosolvent assay (ELISA) and clarified the association between apolipoprotein B (apo B) and MDA-LDL during the fibrate therapy.


RESULTS
Mean MDA-LDL concentrations were higher in healthy men than in healthy women. There were no significant differences in mean MDA-LDL concentrations between age groups for males or females. According to the regression equation (y = 0.063x + 10.9) obtained for apo B and MDA-LDL concentrations with fibrate treatment, the apo B concentration in those may need to be decreased to 1260 mg/l to restore the MDA-LDL concentration to the control concentration (65 +/- 25 units/l). This slope of the apoB/MDA-LDL regression line was approximately half of that with no-drug treatment (y = 0.109x - 10.8).


CONCLUSIONS
Fibrate therapy had an effect on reducing serum MDA-LDL concentration in diabetic patients.
Kondo
Akira
A
Diagnostics Research Laboratories, Daiichi Pure Chemicals Co., 3-1, Kôyodai 3-Chome, Ryugasaki, Ibaraki 301-0852, Japan.
Morita
Hiroshi
H
Nakamura
Hirotoshi
H
Kotani
Kazuo
K
Kobori
Kiichiro
K
Ito
Sachiko
S
Manabe
Mitsuhisa
M
Saito
Kazunori
K
Kanno
Takashi
T
Maekawa
Masato
M
D000328:Adult; D000375:Aging; D001055:Apolipoproteins B / Q000097:blood; D001161:Arteriosclerosis / Q000097:blood / Q000150:complications / Q000378:metabolism / Q000517:prevention & control; D001629:Bezafibrate / Q000494:pharmacology*; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood* / Q000378:metabolism* / Q000628:therapy; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D008077:Lipoproteins, LDL / Q000097:blood* / Q000737:chemistry / Q000187:drug effects / Q000378:metabolism*; D008297:Male; D008315:Malondialdehyde / Q000737:chemistry*; D008875:Middle Aged; D012727:Sex Characteristics
D001055:Apolipoproteins B; D008077:Lipoproteins, LDL; D008315:Malondialdehyde; D001629:Bezafibrate